Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Viral kinetics and sequence analysis of a phase I monotherapy study in subjects with chronic hepatitis B reveals a high barrier of resistance to the capsid assembly modulator ALG-000184

Wednesday, May 7, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the results of a Phase I study evaluating ALG-000184, a capsid assembly modulator, in patients with chronic hepatitis B. The findings reveal a significant barrier to resistance, suggesting the drug's potential effectiveness. The study contributes valuable insights into the management of chronic HBV infection.
Price reaction · baseline $4.36 (2025-05-07 close) · hit after-hours · 5 other ALGS headline(s) in the window, move may be shared
day 0 close
+11.7%
day 1
+2.8%
day 3 · peak
+36.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • High barrier of resistance to ALG-000184 observed in study.
  • Potential for effective treatment of chronic hepatitis B.
  • Phase I study results indicate promising antiviral effects.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is a capsid assembly modulator studied for treating chronic hepatitis B.

What were the results of the Phase I study?

The Phase I study showed a high barrier of resistance to ALG-000184 in patients.

What does a high barrier of resistance mean?

It indicates that the virus is less likely to develop resistance against ALG-000184.

Who were the subjects in the study?

The study involved subjects with chronic hepatitis B infection.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 chronic hepatitis B capsid assembly modulator Phase I study viral kinetics
Last updated: May 7, 2025

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →